摘要
目的 分析肾移植后不同的免疫抑制用药方案对移植肾长期存活的影响。方法 根据不同用药组合将患者分为环孢素A(CsA)、硫唑嘌呤 (Aza)和泼尼松 (Pred)三联治疗组、CsA和Pred二联治疗组、Aza和Pred传统二联治疗组。统计分析免疫抑制用药、排斥反应发生及人、肾存活情况 ;对发生排斥反应的患者追踪其发生排斥前 12个月内的药物更动情况。结果 采用三联治疗的患者人 /肾 5年存活率 (88% / 78% )显著高于传统二联治疗者 (74% / 5 2 % ,P <0 .0 5 ) ,排斥反应发生率也明显低于传统二联治疗者 (P <0 .0 5 ) ;绝大多数发生排斥反应者有减 /停免疫抑制药物史。结论 肾移植后CsA、Aza和Pred三联治疗方案有着较满意的远期疗效 ,明显优于传统二联治疗方案。
Objective To study the influence of different combinations of CsA, Aza and prednisone on renal graft long-term survival. Methods 497 cases of renal transplant recipients with one-year normal graft function were followed up for 5 years. The patients were divided into 3 groups according to the different combinations of immunosuppressive agents (CsA+Aza+Pred, CsA+Pred or Aza+Pred). The transplant recipients' immunosuppressive agents, rejection episodes and survival were analyzed. The drug variation 12 months before graft rejection was retrospectively studied. Results With cyclosporine-based triple therapy, 5-year survival of patient and renal graft was 88*!% and 78*!%, which was significantly higher than traditional double therapy (74*!%/52*!%, P < 0.05 ). The incidence of rejection was significantly reduced ( P < 0.05 ) in the patients receiving cyclosporine-based triple therapy ( P < 0.05 ). The majority of rejection patients used to have a history of drug cessation and reduction. Conclusions Cyclosporine-based triple therapy have a satisfactory long-term result, which is significantly superior to the traditional double therapy.
出处
《中华器官移植杂志》
CAS
CSCD
2000年第5期288-290,共3页
Chinese Journal of Organ Transplantation
关键词
肾移植
环孢菌素
免疫抑制剂
长期存活
Kidney transplantation
Cyclosporine
Immunosuppressive agents
Survivors
